The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response.

ABSTRACT: Checkpoint blockade therapies have changed the clinical management of metastatic melanoma patients considerably, showing survival benefits. Despite the clinical success, not all patients respond to treatment or they develop resistance. Although there are several treatment predictive biomarkers, understanding therapy resistance and the mechanisms of tumor immune evasion is crucial to increase the frequency of patients benefiting from treatment. The PTEN gene is thought to promote immune evasion and is frequently mutated in cancer and melanoma. Another feature of melanoma tumors that may affect the capacity of escaping T-cell recognition is melanoma cell dedifferentiation characterized by decreased expression of the microphtalmia-associated transcription factor (MITF) gene. In

SUBMITTER: Cabrita R 

PROVIDER: S-EPMC7140048 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature